Temporary intraluminal bypass device designed to reduce the rate of diverting stoma and its related complication by at least 70%
The CG-100 device aims to prevent anastomotic leakage in colorectal surgery by creating an internal bypass, improving patient quality of life and reducing healthcare costs significantly.
Projectdetails
Introduction
Anastomotic leakage of colon content into the abdominal cavity is the most devastating complication associated with colorectal surgery. Leaks occur in approximately 22% of cases, leading to increased hospitalization time, higher re-operation rates, increased patient mortality, and additional costs.
Problem Statement
To minimize the risk of a leak, surgeons create a loop of the small bowel which is diverted outside the abdominal wall and connected to a stoma bag to collect the patient’s feces for 4-6 months.
Impact on Patients
- Diverting stoma significantly diminishes patients’ quality of life.
- It increases the cost of care.
- It requires an additional invasive surgery to reverse the stoma.
Solution Overview
Our novel device, CG-100, is an elastic tubular sheath that is positioned at the anastomosis site during the primary colorectal surgery.
Functionality
- CG-100 creates an internal bypass for all colon content.
- It is removed non-surgically 10 days after primary surgery.
Expected Outcomes
CG-100 is expected to improve patient quality of life, save approximately 1350 patient lives annually, and reduce healthcare costs by €4 billion per year in the EU.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.269.312 |
Totale projectbegroting | € 3.241.875 |
Tijdlijn
Startdatum | 1-6-2022 |
Einddatum | 31-5-2025 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- COLOSPAN LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Smart Implant for Magnetic Anastomotic Healing and Leakage EvaluationThe SMARTHEAL project aims to develop a smart magnetic anastomosis implant with integrated micro-sensors for enhanced healing and early detection of leaks, improving surgical outcomes and reducing costs. | EIC Transition | € 2.499.815 | 2025 | Details |
TOP Stapler feasibility studyHet project richt zich op het verbeteren van de circulaire stapeltechniek in darmchirurgie om ischemie en necrose te verminderen, wat de genezing en het succes van anastomosen moet bevorderen. | MIT Haalbaarheid | € 20.000 | 2021 | Details |
Implican StaplerImplican BV ontwikkelt een innovatief apparaat om naadlekkage na darmchirurgie te voorkomen door primaire wondgenezing te bevorderen, met als doel sneller herstel en lagere zorgkosten. | MIT Haalbaarheid | € 20.000 | 2020 | Details |
LAPRIXA: the smallest organ blood pressure measurement device in the worldCorporis Medical onderzoekt de haalbaarheid van het APM-systeem om anastomotische lekkage bij slokdarm- en maagresecties objectief te voorspellen en zo de chirurgische uitkomsten te verbeteren. | MIT Haalbaarheid | € 20.000 | 2020 | Details |
Smart Implant for Magnetic Anastomotic Healing and Leakage Evaluation
The SMARTHEAL project aims to develop a smart magnetic anastomosis implant with integrated micro-sensors for enhanced healing and early detection of leaks, improving surgical outcomes and reducing costs.
TOP Stapler feasibility study
Het project richt zich op het verbeteren van de circulaire stapeltechniek in darmchirurgie om ischemie en necrose te verminderen, wat de genezing en het succes van anastomosen moet bevorderen.
Implican Stapler
Implican BV ontwikkelt een innovatief apparaat om naadlekkage na darmchirurgie te voorkomen door primaire wondgenezing te bevorderen, met als doel sneller herstel en lagere zorgkosten.
LAPRIXA: the smallest organ blood pressure measurement device in the world
Corporis Medical onderzoekt de haalbaarheid van het APM-systeem om anastomotische lekkage bij slokdarm- en maagresecties objectief te voorspellen en zo de chirurgische uitkomsten te verbeteren.